Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 19/20 | 0.63 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TACR2 | P21452 | 1/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.55 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.55 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7300253 | 0.85 | VIPR2 (0.70) | VIPR2 | |
| SCHEMBL7300250 | 0.85 | VIPR2 (0.70) | VIPR2 | |
| SCHEMBL7110730 | 0.85 | VIPR2 (0.66) | VIPR2 | |
| SCHEMBL6466122 | 0.84 | VIPR2 (0.69) | VIPR2 | |
| SCHEMBL17038236 | 0.83 | VIPR2 (0.69) | VIPR2 | |
| SCHEMBL17038205 | 0.82 | VIPR2 (0.81) | VIPR2 | |
| SCHEMBL15714613 | 0.81 | VIPR2 (0.66) | VIPR2 | |
| SCHEMBL15713420 | 0.81 | VIPR2 (0.66) | VIPR2 | |
| SCHEMBL17038231 | 0.81 | VIPR2 (0.64) | VIPR2 | |
| SCHEMBL15713510 | 0.81 | VIPR2 (0.68) | VIPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050027007-A1 | Allylamides useful in the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| EP-1434580-A2 | ALLYLAMIDES USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003030886-A2 | ALLYLAMIDES USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC (US) | 2003-04-17 | — | — | WO | disclosed |
| US-5413999-A | structure is piperazine containing amides | MERCK & CO., INC. (US) | 1995-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050027007-A1 | Allylamides useful in the treatment of alzheimer's disease | BACE1, BACE2, APBA1 | VIPR2 1641/4885ABCC3 1057/4885ABCB11 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.